
ADXSD
Healthcare · Biotechnology · $7.0M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jan 31, 2022
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jun 8, 2022 | Before the open | — | -1.90 | — |
| Feb 14, 2022 | After the close | -3.20 | -3.20 | 0.0% |
| Sep 10, 2021 | Before the open | -3.20 | -1.60 | +50.0% |
| Jun 14, 2021 | After the close | -4.00 | -3.20 | +20.0% |
| Jan 22, 2021 | After the close | — | -7.37 | — |
| Sep 10, 2020 | Before the open | -12.00 | -7.20 | +40.0% |
| Jun 11, 2020 | Before the open | -12.00 | -8.00 | +33.3% |
| Mar 13, 2020 | Before the open | -0.19 | -0.15 | +21.1% |
| Dec 20, 2019 | Before the open | -0.31 | -0.15 | +51.6% |
| Sep 9, 2019 | Before the open | -1.32 | -0.96 | +27.3% |
| Jun 10, 2019 | After the close | -1.20 | -1.32 | -10.0% |
| Mar 12, 2019 | Before the open | -3.75 | -0.88 | +76.5% |
| Jan 10, 2019 | After the close | -2.20 | -4.35 |
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small…
| -97.7% |
| Sep 10, 2018 | After the close | -3.75 | -4.05 | -8.0% |
| Jun 7, 2018 | Before the open | -6.45 | -4.05 | +37.2% |
| Mar 12, 2018 | After the close | -8.25 | -7.35 | +10.9% |